MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$72.81
+4.18%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$71.64
From 52W high−41.21%
Volume189610.00
Market cap$488.71M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$71.64
From 52W high
−41.21%
Volume
189610.00
Market cap
$488.71M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−19.2x
P/E (TTM)
—
RSI (14)
39.2
MomentumView details →
1D Return
+4.18%
YTD Return
+8.39%
SummaryUpdated Jun 1, 2026
Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Wilmette, Illinois. The company went public in December 2019 and focuses on developing innovative therapeutic treatments for cancer patients. As a clinical-stage biotechnology firm, Monopar does not yet generate revenue from product sales but instead operates through research and development activities funded by investor capital and potential partnerships.
Similar companies
Latest newsMore news →
Kim R. Tsuchimoto, a director at Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026, for a total value of $455,566, and exercised options to acquire the same number of shares on the same day.68d agoMonopar Therapeutics reported a net loss of $5.3 million, or $0.62 per share, for Q2 2026, compared to a net loss of $2.5 million, or $0.35 per share, in Q2 2025.85d ago